单位:[1]Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA[2]Huazhong Univ Sci & Technol,Tongji Med Coll,Tongji Hosp,Dept Urol,Wuhan 430030,Peoples R China外科学系华中科技大学同济医学院附属同济医院泌尿外科[3]Huazhong Univ Sci & Technol,Tongji Med Coll,Tongji Hosp,Inst Urol,Wuhan 430030,Peoples R China外科学系华中科技大学同济医学院附属同济医院泌尿外科[4]Huazhong Univ Sci & Technol,Tongji Med Coll,Tongji Hosp,Dept Pediat Surg,Wuhan 430030,Peoples R China儿科学系华中科技大学同济医学院附属同济医院外科学系小儿外科[5]Univ Calif Los Angeles, Dept Comp Sci & Human Genet, Los Angeles, CA 90095 USA[6]Univ Calif Los Angeles, Dept Mol Cell & Dev Biol, Los Angeles, CA 90095 USA[7]Univ Calif Los Angeles, David Geffen Sch Med, Dept Urol, Los Angeles, CA 90095 USA
Metastatic renal cell carcinoma (mRCC) is nearly incurable and accounts for most of the mortality associated with RCC. Von Hippel Lindau (VHL) is a tumour suppressor that is lost in the majority of clear cell RCC (ccRCC) cases. Its role in regulating hypoxia-inducible factors-1 alpha (HIF-1 alpha) and -2 alpha (HIF-2 alpha) is well-studied. Recent work has demonstrated that VHL knock down induces an epithelial-mesenchymal transition (EMT) phenotype. In this study we showed that a CRISPR/Cas9-mediated knock out of VHL in the RENCA model leads to morphologic and molecular changes indicative of EMT, which in turn drives increased metastasis to the lungs. RENCA cells deficient in HIF-1 alpha failed to undergo EMT changes upon VHL knockout. RNA-seq revealed several HIF-1 alpha-regulated genes that are upregulated in our VHL knockout cells and whose overexpression signifies an aggressive form of ccRCC in the cancer genome atlas (TCGA) database. Independent validation in a new clinical dataset confirms the upregulation of these genes in ccRCC samples compared to adjacent normal tissue. Our findings indicate that loss of VHL could be driving tumour cell dissemination through stabilization of HIF-1 alpha in RCC. A better understanding of the mechanisms involved in this phenomenon can guide the search for more effective treatments to combat mRCC.
基金:
UCLA/Caltech Medical Scientist Training Program [T32GM008042]; UCLA Tumour Immunology Training Grant [5T32CA009120]; Cancer Research Coordinating Committee
第一作者单位:[1]Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA
通讯作者:
通讯机构:[1]Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA[7]Univ Calif Los Angeles, David Geffen Sch Med, Dept Urol, Los Angeles, CA 90095 USA
推荐引用方式(GB/T 7714):
Schokrpur Shiruyeh,Hu Junhui,Moughon Diana L.,et al.CRISPR-Mediated VHL Knockout Generates an Improved Model for Metastatic Renal Cell Carcinoma[J].SCIENTIFIC REPORTS.2016,6:doi:10.1038/srep29032.
APA:
Schokrpur, Shiruyeh,Hu, Junhui,Moughon, Diana L.,Liu, Peijun,Lin, Lucia C....&Wu, Lily.(2016).CRISPR-Mediated VHL Knockout Generates an Improved Model for Metastatic Renal Cell Carcinoma.SCIENTIFIC REPORTS,6,
MLA:
Schokrpur, Shiruyeh,et al."CRISPR-Mediated VHL Knockout Generates an Improved Model for Metastatic Renal Cell Carcinoma".SCIENTIFIC REPORTS 6.(2016)